36 h. ago Making U.S. biotech more competitive with China's could help rare disease patients, experts say

Making U.S. biotech more competitive with China's could help rare disease patients, experts say  CNBC

Science

62 h. ago Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase  Yahoo Finance

Events

3 d. ago Caldera launches with $112M, former Morphic CEO and IBD drug from China

Caldera launches with $112M, former Morphic CEO and IBD drug from China  Fierce Biotech

Economics

3 d. ago JPM: Illumina working with China on export troubles, CEO says

JPM: Illumina working with China on export troubles, CEO says  Fierce Biotech

Economics

4 d. ago JPM26, Day 2: Novartis pays $50M cash for China biotech program; AZ acquires AI partner

JPM26, Day 2: Novartis pays $50M cash for China biotech program; AZ acquires AI partner  Fierce Biotech

Economics

6 d. ago Why a biotech pioneer chose China's Greater Bay Area for innovation

Why a biotech pioneer chose China's Greater Bay Area for innovation  news.cgtn.com

Politics

8 d. ago Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe’s ALS business

Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe’s ALS business  Fierce Pharma

Economics

1 week ago Top China Pharma and Biotech Stocks to Watch, According to Bernstein

Top China Pharma and Biotech Stocks to Watch, According to Bernstein  Investing.com

Politics

1 week ago A biotech incubator in China tries to unlock innovation — alongside drugmakers worldwide

A biotech incubator in China tries to unlock innovation — alongside drugmakers worldwide  statnews.com

Events

2 w. ago China’s biopharma sector ‘in prime position to challenge US leadership’

China’s biopharmaceutical sector is said to have entered an “innovation 2.0” phase as it moves to a commercialisation mindset that could see it sideline global competitors and outpace the US – despite restrictive trade policies. In recent years, innovative drug development in the world’s second-largest pharmaceutical market has rapidly approached – and in some cases surpassed – that of the United States, the world’s biggest market. Growing concerns over China’s biotech capabilities have led the...

Politics

2 w. ago China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for drug discovery

Biotech firm Insilico Medicine, backed by the Hong Kong Investment Corporation (HKIC), is building a “digital Einstein” to revolutionise how scientists discover new medicines, and plans to continue expanding its research base in China to stay ahead of global rivals after its Hong Kong listing on Tuesday. “Biotechnology is a high-risk field like a ‘molecular casino’,” said founder Alex Zhavoronkov. “Even with artificial intelligence, you can lose 90 per cent of the time.” The 11-year-old company...

Events

3 w. ago Top biotech scientist Chen Xiaoyuan denies sexual harassment claim, says he will appeal

Biomedical scientist Professor Chen Xiaoyuan denies allegations of sexual harassment and says he will appeal against having his tenure terminated by the National University of Singapore (NUS) over an alleged breach of staff conduct policies. The termination, confirmed to the South China Morning Post by NUS on Wednesday, followed an internal investigation into claims by a female PhD candidate who accused Chen of repeated verbal and physical misconduct since early this year. Chen broke his silence...

Science

3 w. ago Despite geopolitical pressures, China biotech deals remain at pace as collective value soars: Evaluate

Despite geopolitical pressures, China biotech deals remain at pace as collective value soars: Evaluate  Fierce Biotech

Politics

3 w. ago Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Three in four multinational corporations (MNCs) operating in mainland China have maintained or increased their investments in 2025, according to a recent KPMG survey, despite Washington stepping up efforts to decouple from Beijing and its allies following suit. The survey published on Monday, polling 137 senior executives from global companies operating in the world’s second-largest economy between June and September, revealed that only 1 per cent reported preparing to exit the market. About 20...

Economics

3 w. ago Urgent action needed to maintain US global leadership over China in biotech innovation

Urgent action needed to maintain US global leadership over China in biotech innovation  The Pharma Letter

Politics

4 w. ago Patent cliffhanger: will China biotech throw Big Pharma a lifeline?

If pharmaceutical drug patents are an hourglass turned over on the day of approval – with the approaching loss of exclusivity known in the industry as the “patent cliff” – then Big Pharma is currently watching the final grains of sand slipping through the neck of the glass. At the bottom of the hourglass awaits an unforgiving world of generic and biosimilar competition. Between 2025 and 2030, the patent cliff is set to be one of the biggest since 2010 by revenue at risk, according to...

Science

4 w. ago Will China biotech be a hard pill to swallow for US Big Pharma?

Will China biotech be a hard pill to swallow for US Big Pharma?  South China Morning Post

Science

4 w. ago Report warns China drug innovation fast gaining ground on US biotech

Report warns China drug innovation fast gaining ground on US biotech  FirstWord Pharma

Events